Related Experiment Video
Updated: Jul 24, 2026

Three-Dimensional (3D) Tumor Spheroid Invasion Assay
Published on: May 1, 2015
Targeting the STAT pathway in head and neck cancer: recent advances and future prospects
N G Nikitakis1, H Siavash, J J Sauk
1Department of Diagnostic Sciences and Pathology, Dental School, University of Maryland, Baltimore, MD 21201, USA. nin001@dental.umaryland.edu
Abstract:
Head and neck cancer, the sixth most common type of cancer worldwide, is associated with a dismal prognosis that has minimally improved during the last few decades. Future advances in the treatment and prognosis of this fatal disease largely rely upon a better understanding of the molecular events that underlie tumor development and progression, allowing specific targeting of the involved molecules and pathways. In this context, recent efforts have revolved around a family of transcription factors known as STATs (signal transducers and activators of transcription). STAT proteins comprise a family of latent cytoplasmic transcription factors that become transiently activated in response to extracellular signals, leading to regulation of diverse physiological responses. There is compelling evidence that persistent activation of specific STAT molecules, especially Stat3 and Stat5, possesses oncogenic properties in a number of human cancers, including head and neck cancer. The presence of constitutively activated STAT molecules in cancer cells is mainly attributed to the dysregulation of upstream activating pathways and the aberration of negative regulatory mechanisms. The end result is induction of specific target genes that stimulate cell proliferation, prevent apoptosis, promote angiogenesis and facilitate tumor immune evasion. Therefore, targeting and disruption of oncogenic STAT signaling may theoretically be accomplished through various approaches, involving direct (e.g. interference with the various facets of STAT expression, activation or function) and indirect strategies (e.g. inhibition of upstream signaling events and enhancement or restoration of negative regulatory mechanisms). The availability of multiple potential targets for interruption of aberrant STAT signaling in cancer and the thus-far promising results have generated optimism for the clinical applicability of STAT targeting in head and neck cancer, which is the focus of this review.
Insights
Targeting signal transducers and activators of transcription (STATs), particularly Stat3 and Stat5, offers a promising strategy for treating head and neck cancer. Disrupting aberrant STAT signaling may improve patient prognosis by inhibiting tumor growth and spread.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Head and neck cancer has a poor prognosis with limited treatment advancements.
- Understanding molecular drivers is crucial for developing targeted therapies.
- Signal transducers and activators of transcription (STATs) are implicated in various cancers.
Purpose of the Study:
- To review the role of STAT signaling in head and neck cancer development and progression.
- To explore potential therapeutic strategies targeting STAT pathways in this disease.
- To highlight the clinical applicability of STAT-targeting agents.
Main Methods:
- Review of existing literature on STATs in head and neck cancer.
- Analysis of molecular mechanisms underlying STAT activation and function in tumorigenesis.
- Discussion of direct and indirect therapeutic approaches to inhibit STAT signaling.
Main Results:
- Persistent activation of STATs (especially Stat3 and Stat5) contributes to head and neck cancer.
- Aberrant STAT signaling drives proliferation, inhibits apoptosis, promotes angiogenesis, and aids immune evasion.
- Dysregulation of upstream pathways and impaired negative feedback loops lead to constitutive STAT activation.
Conclusions:
- Targeting oncogenic STAT signaling presents a viable therapeutic strategy for head and neck cancer.
- Multiple molecular targets within the STAT pathway offer opportunities for drug development.
- Promising preclinical results support the clinical translation of STAT-targeting therapies.
More Related Videos
Related Concept Videos
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

